Follow @TheHPRA
Contact us
Glossary
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Xeljanz (tofacitinib) - Important Safety Information from Pfizer Healthcare Ireland as approved by HPRA
Notice type:
3rd Party Publications
Date:
28/03/2019
Problem Or Issue:
Important Safety Information communication from Pfizer Healthcare Ireland on increased risk of pulmonary embolism and mortality in rheumatoid arthritis patients receiving 10 mg twice daily in a clinical trial
Important Safety Information - Xeljanz (tofacitinib)
« Back
Date Printed: 25/05/2022